GAVRETO® (Pralsetinib)

The FDA on September 4, 2020 granted accelerated approval to GAVRETO® for adult patients with metastatic RET fusion-positive Non-Small Cell Lung Cancer (NSCLC), as detected by an FDA approved test. GAVRETO® is a product of Blueprint Medicines Corporation.